OBX (Obsidian Therapeutics) Debt-to-Equity: -0.02 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OBX Obsidian Therapeutics Inc OBX
8 GF Score
Price $27.50
View Full Analysis

What is Obsidian Therapeutics Debt-to-Equity?

Obsidian Therapeutics OBX -1.79% 8 Debt-to-Equity is -0.02 as of Dec. 2025. GuruFocus rates OBX with a GF Score™ of 8/100.

Obsidian Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $3.06 Mil. Obsidian Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $1.22 Mil. Obsidian Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $-266.04 Mil. Obsidian Therapeutics's debt to equity for the quarter that ended in Dec. 2025 was -0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Obsidian Therapeutics's Debt-to-Equity or its related term are showing as below:

OBX's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

Obsidian Therapeutics  (NAS:OBX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Obsidian Therapeutics Debt-to-Equity Related Terms

Obsidian Therapeutics Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Obsidian Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Obsidian Therapeutics Debt-to-Equity Chart

Obsidian Therapeutics Annual Data
Trend Dec24 Dec25
Debt-to-Equity
-0.04 -0.02

Obsidian Therapeutics Semi-Annual Data
Dec24 Dec25
Debt-to-Equity -0.04 -0.02

OBX vs : Debt-to-Equity Comparison

For the Biotechnology subindustry, Obsidian Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Obsidian Therapeutics Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Obsidian Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Obsidian Therapeutics's Debt-to-Equity falls into.


OBX
8GF Score
Obsidian Therapeutics Inc OBX
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Obsidian Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Obsidian Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.059 + 1.224) / -266.037
=-0.02

Obsidian Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.059 + 1.224) / -266.037
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.02 mean?
Obsidian Therapeutics (OBX) has a Debt-to-Equity of -0.02 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Obsidian Therapeutics and its competitors.
Is Obsidian Therapeutics' Debt-to-Equity too high?
Obsidian Therapeutics' current Debt-to-Equity is -0.02. Overall, Obsidian Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Obsidian Therapeutics' Debt-to-Equity compare to ?
Obsidian Therapeutics' Debt-to-Equity of -0.02 can be compared against companies in the Biotechnology industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 971 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Obsidian Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Obsidian Therapeutics's current Debt-to-Equity is -0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Obsidian Therapeutics stock overvalued right now?
Obsidian Therapeutics (OBX) has a current Debt-to-Equity of -0.02. The current Debt-to-Equity is -0.02. Obsidian Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Obsidian Therapeutics (OBX), the current Debt-to-Equity is -0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Obsidian Therapeutics Business Description

Comparable Companies
Address 1030 Massachusetts Avenue, Suite 400, Cambridge, MA, USA, 02138
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
8GF Score

Get the complete analysis for OBX

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.50
Price